
  
    
      
        Background_NNP
        Extensive_NNP bone_NN marrow_NN infiltration_NN with_IN cancer_NN cells_NNS and_CC
        anticancer_NN therapy_NN lead_NN to_TO immune_JJ incompetence_NN in_IN children_NNS
        with_IN cancer_NN [_NN 1_CD 2_CD ]_NN ._. Since_IN the_DT prognosis_NN and_CC overall_JJ
        survival_NN of_IN children_NNS with_IN cancer_NN have_VBP dramatically_RB improved_VBN
        during_IN past_JJ 30_CD years_NNS [_NN 3_CD ]_NN ,_, problems_NNS remain_VBP related_VBN to_TO
        infections_NNS ,_, mainly_RB during_IN leukopenic_JJ periods_NNS [_NN 3_CD 4_CD 5_CD ]_NN ._.
        Causal_NNP pathogens_NNS of_IN febrile_NN neutropenia_NN (_( FN_NNP )_) ,_, most_RBS
        frequently_RB bacterial_JJ or_CC fungal_NN ,_, are_VBP identified_VBN and_CC
        confirmed_VBN by_IN culture_NN in_IN 25_CD -_: 35_CD %_NN of_IN the_DT cases_NNS [_NN 3_CD 6_CD ]_NN ._. In_IN
        other_JJ 15_CD -_: 25_CD %_NN of_IN patients_NNS with_IN FN_NNP ,_, bacterial_JJ or_CC fungal_NN
        pathogens_NNS are_VBP suspected_VBN clinically_RB ._. The_DT remaining_VBG 50_CD %_NN of_IN
        cases_NNS are_VBP classified_VBN as_IN a_DT fever_NN of_IN unknown_JJ origin_NN (_( FUO_NNP )_) and_CC
        may_MD be_VB caused_VBN by_IN other_JJ pathogens_NNS ,_, namely_RB viruses_NNS ,_, that_WDT are_VBP
        more_RBR difficult_JJ to_TO detect_VB by_IN conventional_JJ diagnostic_JJ methods_NNS
        [_NN 7_CD 8_CD 9_CD ]_NN ._.
        Lymphotropic_NNP herpesviruses_NNS (_( LH_NNP )_) Epstein-_NNP Barr_NNP virus_NN
        (_( EBV_NNP )_) ,_, cytomegalovirus_JJ (_( CMV_NNP )_) and_CC human_JJ herpesvirus-_NN 6_CD
        (_( HHV-_NNP 6_CD )_) establish_VB a_DT lifelong_JJ persistent_JJ infection_NN in_IN a_DT
        great_JJ majority_NN of_IN humans_NNS ._. They_PRP usually_RB produce_VBP inaparent_NN
        infection_NN or_CC transient_JJ immune_JJ compromise_NN in_IN otherwise_RB
        healthy_JJ hosts_NNS but_CC are_VBP able_JJ to_TO cause_VB life-threatening_JJ
        primary_JJ or_CC reactivated_VBD infections_NNS in_IN individuals_NNS with_IN
        congenital_NN or_CC acquired_VBN T-_NNP cell_NN immunodeficiencies_NNS [_NN 7_CD 8_CD 9_CD 10_CD
        11_CD 12_CD 13_CD 14_CD 15_CD ]_NN ._. The_DT spectrum_NN of_IN diseases_NNS caused_VBN by_IN
        lymphotropic_JJ herpesviruses_NNS is_VBZ well_RB documented_VBN in_IN patients_NNS
        undergoing_VBG bone_NN marrow_NN transplantation_NN (_( BMT_NNP )_) [_NN 8_CD 9_CD 10_CD 11_CD ]_NN
        or_CC organ_NN transplantation_NN [_NN 12_CD 13_CD ]_NN and_CC in_IN individuals_NNS
        infected_VBN with_IN human_JJ immunodeficiency_NN virus_NN (_( HIV_NNP )_) [_NN 14_CD 15_CD ]_NN
        ._. In_IN patients_NNS undergoing_VBG conventional_JJ anticancer_NN therapy_NN
        without_IN BMT_NNP ,_, the_DT data_NNS focusing_VBG on_IN EBV_NNP ,_, CMV_NNP or_CC HHV-_NNP 6_CD
        infection_NN are_VBP scarcely_RB documented_VBN and_CC mostly_RB reported_VBD as_IN
        individual_JJ cases_NNS [_NN 16_CD 17_CD 18_CD 19_CD ]_NN ._. With_IN combined_VBN diagnostic_JJ
        approach_NN of_IN serology_NN and_CC viral_JJ DNA_NNP detection_NN we_PRP performed_VBD a_DT
        prospective_JJ study_NN of_IN children_NNS undergoing_VBG non-_NN BMT_NNP therapy_NN
        for_IN cancer_NN to_TO demostrate_NN the_DT incidence_NN of_IN LH_NNP
        infections_NNS ._.
      
      
        Methods_NNP
        
          Patients_NNS and_CC controls_NNS
          Two_CD hundred_CD and_CC nine_CD Caucasian_NNP children_NNS and_CC
          adolescents_NNS 4_CD months_NNS to_TO 17_CD years_NNS old_JJ at_IN the_DT time_NN of_IN
          cancer_NN diagnosis_NN were_VBD eligible_JJ for_IN this_DT prospective_JJ
          Institutional_NNP Review_NNP Board_NNP approved_VBD single-center_JJ study_NN
          performed_VBN at_IN the_DT Department_NNP of_IN Pediatrics_NNP ,_, Masaryk_NNP
          University_NNP in_IN Brno_NNP ,_, Czech_NNP Republic_NNP ._. Inclusion_NNP criteria_NNS
          for_IN patients_NNS included_VBD :_: presence_NN of_IN cancer_NN ,_, serology_NN of_IN
          EBV_NNP and_CC CMV_NNP at_IN least_JJS at_IN the_DT time_NN of_IN cancer_NN diagnosis_NN
          (_( pre-treatment_JJ sample_NN )_) and_CC 2_CD months_NNS after_IN the_DT end_NN of_IN
          anticancer_NN therapy_NN (_( post-treatment_JJ sample_NN )_) ._. Children_NNS with_IN
          cancer_NN undergoing_VBG BMT_NNP ,_, human_JJ immunodeficiency_NN virus_NN
          positive_JJ children_NNS ,_, and_CC children_NNS who_WP died_VBD while_IN on_IN
          anticancer_NN therapy_NN were_VBD excluded_VBN from_IN the_DT study_NN ._. All_DT
          children_NNS were_VBD treated_VBN according_VBG to_TO approved_VBD current_JJ
          protocols_NNS for_IN therapy_NN of_IN pediatric_JJ malignancies_NNS
          (_( Berlin-_NNP Frankfurt-_NNP Münster_NNP protocols_NNS for_IN therapy_NN of_IN
          leukemia_NN and_CC non-_NN Hodgkin_NNP 's_POS lymphoma_NN ;_: Histiocyte_NNP Society_NNP
          protocols_NNS for_IN therapy_NN of_IN histiocytoses_NNS ;_: International_NNP
          Pediatric_NNP Oncology_NNP Society_NNP protocols_NNS for_IN treatment_NN of_IN
          Hodgkin_NNP 's_POS disease_NN and_CC solid_JJ tumors_NNS except_IN for_IN
          neuroblastoma_NN which_WDT has_VBZ been_VBN treated_VBN according_VBG to_TO
          Pediatric_NNP Oncology_NNP Group_NNP protocols_NNS )_) ._. As_IN a_DT supportive_JJ
          care_NN ,_, leukodepleted_JJ (_( containing_VBG <_NN 10_CD 5_CD leukocytes_NNS per_IN
          one_CD transfusion_NN unit_NN )_) irradiated_JJ (_( 50_CD Gy_NNP )_) blood_NN products_NNS
          (_( packed_VBN red_JJ blood_NN cells_NNS ;_: platelets_NNS obtained_VBN by_IN apheresis_NNS
          from_IN one_CD donor_NN )_) were_VBD given_VBN only_RB ._. Finally_RB ,_, 186_CD children_NNS
          and_CC adolescents_NNS ,_, 101_CD males_NNS and_CC 85_CD females_NNS ,_, met_VBD the_DT
          inclusion_NN criteria_NNS ;_: remaining_VBG 23_CD children_NNS did_VBD not_RB meet_VB
          that_IN criteria_NNS since_IN they_PRP move_VBP or_CC their_PRP$ initial_JJ or_CC
          follow-up_JJ samples_NNS were_VBD missing_VBG ._.
          One_CD hundred_CD and_CC sixteen_NN consecutive_JJ patients_NNS were_VBD
          studied_VBN from_IN 1993_CD through_IN 1996_CD ._. In_IN addition_NN ,_, in_IN
          consecutive_JJ 70_CD patients_NNS studied_VBN from_IN 1997_CD through_IN 1999_CD ,_,
          serology_NN of_IN HHV-_NNP 6_CD at_IN the_DT same_JJ time-points_JJ as_IN for_IN EBV_NNP and_CC
          CMV_NNP ,_, and_CC monitoring_NN of_IN EBV_NNP ,_, CMV_NNP and_CC HHV-_NNP 6_CD DNA_NNP was_VBD also_RB
          performed_VBN ._. If_IN a_DT sample_NN was_VBD positive_JJ for_IN LH_NNP DNA_NNP ,_, repeated_VBN
          samples_NNS every_DT 5_CD -_: 7_CD days_NNS were_VBD performed_VBN until_IN negative_NN ._.
          During_IN anticancer_NN therapy_NN ,_, samples_NNS of_IN peripheral_JJ blood_NN
          for_IN serology_NN and_CC LH_NNP DNA_NNP study_NN were_VBD taken_VBN as_RB clinically_RB
          indicated_VBD in_IN the_DT following_JJ situations_NNS :_: (_( 1_LS )_) FN_NNP (_( defined_VBN as_IN
          a_DT single_JJ episode_NN of_IN oral_JJ temperature_NN ≥_NN 38_CD ._. 5_LS °_NN C_NNP or_CC at_IN least_JJS
          two_CD episodes_NNS of_IN oral_JJ temperature_NN ≥_NN 38_CD °_NN C_NNP appearing_VBG at_IN
          least_JJS 12_CD hours_NNS apart_RB in_IN a_DT patient_NN with_IN absolute_JJ
          neutrophil_NN count_NN ≤_NN 500_CD /_NN ml_NN )_) ;_: (_( 2_LS )_) fever_NN of_IN unknown_JJ origin_NN
          (_( FUO_NNP )_) (_( defined_VBN as_IN oral_JJ temperature_NN ≥_NN 37_CD °_NN C_NNP lasting_JJ for_IN at_IN
          least_JJS 7_CD days_NNS and_CC no_DT infectious_JJ or_CC non-infectious_JJ cause_NN of_IN
          the_DT fever_NN has_VBZ been_VBN identified_VBN )_) ;_: (_( 3_LS )_) lymphadenopathy_NN ,_,
          hepatomegaly_RB or_CC splenomegaly_RB not_RB associated_VBN directly_RB with_IN
          the_DT diagnosis_NN or_CC relapse_NN of_IN the_DT cancer_NN ;_: (_( 4_LS )_) liver_NN enzymes_NNS
          (_( aspartataminotransferase_NN or_CC alaninaminotransferase_NN )_)
          elevation_NN above_IN 2_CD standard_JJ deviations_NNS of_IN normal_JJ values_NNS ;_:
          (_( 5_LS )_) protracted_JJ (_( ≥_NN 14_CD days_NNS )_) bone_NN marrow_NN aplasia_NN (_( defined_VBN
          as_IN presence_NN of_IN at_IN least_JJS two_CD of_IN the_DT following_VBG :_: leukocytes_NNS
          ≤_NN 1_CD ,_, 000_CD /_NN ml_NN ,_, thrombocytes_NNS ≤_NN 30_CD ,_, 000_CD /_NN ml_NN ,_, hemoglobin_NN ≤_NN 80_CD g_SYM /_NN l_NN
          in_IN peripheral_JJ blood_NN )_) without_IN the_DT evidence_NN of_IN
          chemotherapy-_NN or_CC radiotherapy-induced_JJ aplasia_NN ;_: (_( 6_CD )_)
          gastroenteritis_NNS ;_: (_( 7_CD )_) atypical_JJ pneumonia_NN ;_: (_( 8_CD )_) exanthema_NN ;_:
          and_CC (_( 9_CD )_) encephalopathy_NN ._. Infection_NNP associated_VBN with_IN at_IN
          least_JJS one_CD of_IN the_DT symptoms_NNS mentioned_VBN above_IN and_CC confirmed_VBN
          by_IN serology_NN or_CC in_IN combination_NN with_IN viral_JJ DNA_NNP detection_NN
          was_VBD designated_VBN as_IN "_'' symptomatic_JJ infection_NN "_'' ._.
          The_DT population_NN was_VBD studied_VBN according_VBG to_TO cancer_NN
          diagnosis_NN (_( leukemia_NN ,_, lymphoma_NN and_CC solid_JJ tumor_NN )_) and_CC
          according_VBG to_TO the_DT age_NN at_IN the_DT time_NN of_IN a_DT particular_JJ sample_NN
          has_VBZ been_VBN taken_VBN ._. Based_VBN on_IN age_NN at_IN the_DT time_NN when_WRB a_DT
          pre-treatment_JJ sample_NN was_VBD taken_VBN ,_, four_CD age_NN groups_NNS has_VBZ been_VBN
          made_VBN :_: 0_CD -_: 1_CD year_NN old_JJ (_( consisting_VBG of_IN 25_CD children_NNS )_) ;_: 2_CD -_: 5_CD years_NNS
          old_JJ (_( 49_CD children_NNS )_) ;_: 6_CD -_: 11_CD years_NNS old_JJ (_( 52_CD children_NNS )_) ;_: and_CC
          12_CD -_: 17_CD years_NNS old_JJ (_( 60_CD children_NNS )_) ._. A_DT total_NN of_IN 218_CD children_NNS 4_CD
          months_NNS to_TO 17_CD years_NNS old_JJ (_( 31_CD ,_, 54_CD ,_, 62_CD ,_, 71_CD children_NNS in_IN age_NN
          group_NN 0_CD -_: 1_CD ,_, 2_CD -_: 5_CD ,_, 6_CD -_: 11_CD ,_, 12_CD -_: 17_CD years_NNS ,_, respectively_RB )_) and_CC 165_CD
          adults_NNS 19_CD -_: 78_CD years_NNS old_JJ without_IN infectious_JJ or_CC febrile_NN
          illness_NN who_WP underwent_VBD minor_JJ surgery_NN procedure_NN and_CC
          provided_VBD a_DT blood_NN sample_NN for_IN that_DT purpose_NN ,_, served_VBD as_IN a_DT
          healthy_JJ controls_NNS for_IN serology_NN testing_NN ._. 64_CD children_NNS from_IN
          that_DT group_NN provided_VBD samples_NNS of_IN peripheral_JJ blood_NN for_IN LH_NNP
          DNA_NNP analysis_NN too_RB ._. Informed_NNP consent_NN has_VBZ been_VBN taken_VBN from_IN
          all_DT adults_NNS and_CC parents_NNS /_NN legal_JJ guardians_NNS of_IN all_PDT the_DT
          children_NNS ._.
        
        
          Serology_NNP of_IN LH_NNP
          All_DT samples_NNS were_VBD tested_VBN by_IN commercially_RB available_JJ
          sets_NNS ._. ELISA_NNP testing_NN kit_NN (_( DIESSE_NNP ®_NN ,_, Germany_NNP )_) was_VBD used_VBN to_TO
          test_VB the_DT EBV_NNP VCA_NNP IgM_NNP ,_, EBV_NNP VCA_NNP IgG_NNP ,_, EBV_NNP EBNA_NNP IgG_NNP
          antibodies_NNS [_NN 20_CD ]_NN and_CC ELISA_NNP testing_NN kit_NN (_( MEDAC_NNP ®_NN ,_, Czech_NNP
          Republic_NNP )_) was_VBD used_VBN to_TO test_VB the_DT CMV_NNP IgM_NNP and_CC CMV_NNP IgG_NNP
          antibodies_NNS in_IN patient_NN sera_NN [_NN 21_CD ]_NN ._. Immunofluorescence_NNP
          assay_NN (_( IFA_NNP )_) kit_NN (_( BAG_NNP ®_NN ,_, Germany_NNP )_) was_VBD used_VBN to_TO test_VB the_DT
          HHV-_NNP 6_CD IgM_NNP and_CC HHV-_NNP 6_CD IgG_NNP antibodies_NNS [_NN 22_CD ]_NN ._. All_DT tests_NNS
          were_VBD performed_VBN according_VBG to_TO manufacturer_NN 's_POS instructions_NNS ._.
          To_TO avoid_VB misinterpretation_NN of_IN results_NNS ,_, all_DT samples_NNS from_IN
          each_DT patient_NN were_VBD titrated_JJ and_CC tested_VBN at_IN the_DT same_JJ time_NN ._.
          The_DT titer_NN results_NNS were_VBD expressed_VBN semiquantitatively_RB in_IN
          four_CD grades_NNS :_: negative_JJ (_( -_: )_) ;_: mildly_RB positive_JJ (_( +_NN )_) ;_: moderately_RB
          positive_JJ (_( +_NN +_NN )_) ;_: strongly_RB positive_JJ (_( +_NN +_NN +_NN )_) for_IN each_DT antibody_NN
          tested_VBN ._.
          The_DT presence_NN of_IN EBV_NNP VCA_NNP IgM_NNP positivity_NN (_( of_IN any_DT grade_NN )_)
          followed_VBN by_IN EBV_NNP VCA_NNP IgG_NNP positivity_NN (_( of_IN any_DT grade_NN )_) or_CC
          increasing_VBG EBV_NNP VCA_NNP IgG_NNP positivity_NN with_IN negative_JJ EBV_NNP EBNA_NNP
          IgG_NNP 14_CD -_: 21_CD days_NNS after_IN an_DT initial_JJ level_NN was_VBD measured_VBN was_VBD
          considered_VBN as_IN a_DT recent_JJ primary_JJ EBV_NNP infection_NN ._. EBV_NNP EBNA_NNP
          IgG_NNP positive_JJ (_( of_IN any_DT grade_NN )_) case_NN with_IN the_DT presence_NN of_IN the_DT
          same_JJ pattern_NN of_IN EBV_NNP VCA_NNP IgM_NNP and_CC /_NN or_CC EBV_NNP VCA_NNP IgG_NNP positivity_NN
          as_IN in_IN the_DT primary_JJ infection_NN was_VBD considered_VBN as_IN an_DT EBV_NNP
          reactivation_NN ._. In_IN case_NN of_IN CMV_NNP and_CC HHV-_NNP 6_CD ,_, the_DT presence_NN of_IN
          IgM_NNP class_NN antibody_NN positivity_NN (_( of_IN any_DT grade_NN )_) followed_VBN by_IN
          IgG_NNP positivity_NN (_( of_IN any_DT grade_NN )_) ,_, or_CC increasing_VBG IgG_NNP
          positivity_NN 14_CD -_: 21_CD days_NNS after_IN an_DT initial_JJ level_NN was_VBD
          measured_VBN ,_, was_VBD considered_VBN as_IN a_DT primary_JJ CMV_NNP or_CC HHV-_NNP 6_CD
          infection_NN ._. IgM_NNP positivity_NN (_( of_IN any_DT grade_NN )_) in_IN a_DT patient_NN
          previously_RB IgG_NNP positive_NN was_VBD considered_VBN as_IN a_DT reactivation_NN
          of_IN CMV_NNP or_CC HHV-_NNP 6_CD ._.
        
        
          DNA_NN analysis_NN of_IN LH_NNP
          Whole_JJ blood_NN samples_NNS were_VBD collected_VBN in_IN K_NNP 
          3_CD EDTA_NNP tubes_NNS (_( Sarstedt_NNP )_) ._. Nucleic_NNP acids_NNS
          were_VBD isolated_VBN using_VBG silica-based_JJ Nucleic_NNP Acids_NNP Isolation_NNP
          Kit_NNP (_( Malamite_NNP ,_, Czech_NNP Republic_NNP )_) ._. For_IN EBV_NNP DNA_NNP detection_NN two_CD
          primer_NN pairs_NNS EBER_NNP 3_CD (_( 5_CD '_POS gca_NN acg_NN gct_NN gct_NN ctg_NN ttt_NN ga_NN )_) ,_, EBER_NNP
          5_CD (_( 5_CD '_POS gtg_NN gtc_NN cgc_NN atg_NN ttt_NN tga_NN tc_NN )_) and_CC TC_NNP 60_CD (_( 5_CD '_POS cca_NN gag_NN
          gta_NN agt_NN gga_NN ctt_NN )_) ,_, TC_NNP 61_CD (_( 5_CD '_POS gac_NN cgg_NN tgc_NN ctt_NN ctt_NN agg_NN )_) were_VBD
          used_VBN ._. The_DT lengths_NNS of_IN EBER-_NNP and_CC TC_NNP 6_CD -_: specific_JJ amplification_NN
          products_NNS were_VBD 192_CD bp_NN and_CC 119_CD bp_NN ,_, respectively_RB ._. The_DT HCMV_NNP
          DNA_NNP was_VBD detected_VBN using_VBG HCMV_NNP 1_CD (_( 5_CD '_POS cct_NN agt_NN gtg_NN gat_NN gac_NN cta_NN
          cgg_NN gcc_NN a_DT )_) and_CC HCMV_NNP 2_CD (_( 5_CD '_POS cag_NN aca_NN cag_NN tgt_NN cct_NN ccc_NN gct_NN cct_NN
          c_SYM )_) primers_NNS producing_VBG 249_CD bp_NN long_JJ amplicon_NN and_CC the_DT DNA_NNP of_IN
          HHV_NNP 6_CD was_VBD amplified_VBN with_IN specific_JJ primer_NN pair_NN HP_NNP 0_CD (_( 5_CD '_POS ccg_NN
          caa_NN tcg_NN aat_NN cca_NN cct_NN agc_NN gg_NN )_) and_CC HP_NNP 4_CD (_( 5_CD '_POS gtg_NN aga_NN acg_NN gat_NN
          tcg_NN aac_NN agt_NN gct_NN g_SYM )_) yielding_VBG 440_CD bp_NN product_NN [_NN 23_CD 24_CD ]_NN ._.
          All_DT amplifications_NNS were_VBD carried_VBN out_IN with_IN 20_CD pmol_NN of_IN each_DT
          primer_NN in_IN 2_CD mM_NN solution_NN of_IN MgCl_NNP 
          2_CD ,_, 2_CD U_NNP of_IN Tag_NNP Special_JJ DNA_NNP polymerase_NN
          (_( Biovendor_NNP ,_, Czech_NNP Republic_NNP )_) ,_, 0_CD ._. 3_CD mM_NN of_IN each_DT dNTPs_NNS ,_, 10_CD ×_NN
          reaction_NN buffer_NN and_CC 1_CD μg_NN of_IN isolated_VBN DNA_NNP according_VBG to_TO the_DT
          following_JJ conditions_NNS :_: 96_CD °_NN C_NNP for_IN 4_CD min_NN ,_, (_( 94_CD °_NN C_NNP for_IN 10_CD sec_NN ,_,
          58_CD °_NN C_NNP for_IN 10_CD sec_NN ,_, 72_CD °_NN C_NNP for_IN 20_CD sec_NN )_) 36_CD times_NNS ,_, and_CC final_JJ
          extension_NN at_IN 72_CD °_NN C_NNP for_IN 2_CD min_NN ._. The_DT reactions_NNS were_VBD done_VBN in_IN
          the_DT thermocycler_NN PTC_NNP 200_CD (_( MJ_NNP Research_NNP )_) ._. The_DT products_NNS
          amplified_VBN were_VBD run_VBN on_IN 3_CD %_NN agarose_NN gel_NN (_( Lachema_NNP ,_, Brno_NNP ,_,
          Czech_NNP Republic_NNP )_) and_CC detected_VBN by_IN UV_NNP illuminator_NN at_IN 312_CD nm_NN
          after_IN staining_VBG with_IN ethidium_NN bromide_NN (_( 5_CD μg_NN /_NN ml_NN )_) ._.
          Electrophoretograms_NNP were_VBD scanned_JJ by_IN CCD_NNP camera_NN (_( UltraLum_NNP )_)
          and_CC the_DT relative_JJ quantities_NNS were_VBD estimated_VBN (_( expressed_VBD as_IN
          follow_VB :_: (_( +_NN )_) =_SYM under_IN 100_CD ,_, (_( +_NN +_NN )_) from_IN 100_CD to_TO 10_CD ,_, 000_CD ,_, (_( +_NN +_NN +_NN )_) =_SYM
          more_JJR than_IN 10_CD ,_, 000_CD viruses_NNS per_IN 10_CD 5_CD peripheral_JJ leukocytes_NNS
          processed_VBN )_) according_VBG the_DT densities_NNS of_IN pathogen-specific_JJ
          bands_NNS measured_VBN by_IN Scionlmage_NNP ®_NN software_NN ,_, using_VBG the_DT
          standard_JJ curves_NNS of_IN positive_JJ controls_NNS ,_, which_WDT were_VBD derived_VBN
          from_IN 10_CD -_: fold_VB dilution_NN scales_NNS ._. The_DT set_NN of_IN "_'' negative_JJ
          control_NN "_'' (_( 1_CD μl_NN of_IN water_NN instead_RB of_IN isolated_VBN DNA_NNP )_) ,_,
          "_'' negative_JJ isolation_NN control_NN "_'' (_( virus-free_JJ blood_NN sample_NN )_)
          and_CC "_'' inhibition_NN controls_NNS "_'' (_( 1_CD μl_NN of_IN each_DT isolate_VB added_VBN in_IN
          the_DT reaction_NN with_IN 1_CD μl_NN of_IN positive_JJ control_NN DNA_NNP )_) as_RB well_RB
          as_RB the_DT "_'' positive_JJ control_NN "_'' (_( only_RB with_IN 1_CD μl_NN of_IN positive_JJ
          control_NN DNA_NNP =_SYM recombinatnt_NN plasmids_NNS with_IN inserted_VBN
          amplicons_NNS )_) was_VBD additionaly_RB amplified_VBN to_TO reduce_VB the_DT risk_NN
          of_IN false_JJ positive_NN and_CC /_NN or_CC false_JJ negative_JJ results_NNS ._. Any_DT
          positivity_NN detected_VBN by_IN PCR_NNP followed_VBN by_IN serology_NN results_NNS
          demonstrating_VBG recent_JJ LH_NNP infection_NN 1_CD to_TO 5_CD weeks_NNS later_RB was_VBD
          considered_VBN as_IN an_DT active_JJ infection_NN ._.
        
        
          Statistical_NNP analysis_NN
          Unconditional_NNP logistic_JJ regression_NN analysis_NN was_VBD
          performed_VBN with_IN pre-treatment_JJ (_( presence_NN or_CC absence_NN of_IN
          virus_NN )_) as_IN the_DT dichotomous_JJ outcome_NN measure_NN ._. For_IN this_DT
          analysis_NN group_NN (_( patients_NNS or_CC controls_NNS )_) ,_, age_NN (_( as_IN a_DT
          continuous_JJ variable_JJ )_) ,_, and_CC the_DT interaction_NN of_IN age_NN and_CC
          group_NN were_VBD the_DT independent_JJ measures_NNS ._. This_DT analysis_NN was_VBD
          repeated_VBN for_IN each_DT viral_JJ serology_NN ._. To_TO control_VB for_IN age_NN ,_,
          logistic_JJ regressions_NNS were_VBD performed_VBN within_IN each_DT age_NN group_NN
          (_( 0_CD -_: 1_CD ;_: 2_CD -_: 5_CD ;_: 6_CD -_: 11_CD ;_: and_CC 12_CD -_: 17_CD )_) for_IN each_DT viral_JJ serology_NN with_IN
          group_NN as_IN the_DT only_RB independent_JJ variable_NN ._. These_DT analyses_NNS
          provide_VBP estimates_NNS and_CC confidence_NN intervals_NNS of_IN the_DT odds_NNS
          ratios_NNS of_IN seroprevalence_NN for_IN pre-treatment_JJ cases_NNS versus_CC
          controls_NNS adjusting_VBG for_IN age_NN ._. The_DT same_JJ set_NN of_IN analyses_NNS was_VBD
          performed_VBN with_IN post-transplant_JJ cases_NNS versus_CC controls_NNS ._.
          To_TO study_VB pre-treatment_JJ versus_CC post-treatment_JJ patient_NN
          samples_NNS ,_, a_DT McNemar_NNP test_NN was_VBD performed_VBN for_IN each_DT viral_JJ
          serology_NN ._. McNemar_NNP 's_POS test_NN determines_VBZ the_DT degree_NN of_IN
          agreement_NN between_IN two_CD paired_VBN variables_NNS ._. This_DT test_NN was_VBD
          performed_VBN both_DT overall_NN ,_, ignoring_VBG age_NN ,_, and_CC then_RB repeated_VBN
          within_IN each_DT age_NN group_NN ._. For_IN the_DT comparison_NN of_IN transfused_JJ
          and_CC non-transfused_JJ patients_NNS ,_, chi-square_JJ test_NN was_VBD used_VBN [_NN
          25_CD ]_NN ._.
        
      
      
        Results_NNS
        
          Serology_NNP of_IN LH_NNP
          Before_IN grouping_VBG the_DT ages_NNS ,_, a_DT logistic_JJ regression_NN
          analysis_NN was_VBD performed_VBN with_IN each_DT viral_JJ pre-treatment_JJ
          sample_NN as_IN the_DT dichotomous_JJ outcome_NN measure_NN and_CC group_NN
          (_( patients_NNS or_CC controls_NNS )_) as_IN the_DT independent_JJ measure_NN with_IN
          age_NN as_IN a_DT covariate_NN and_CC including_VBG the_DT age_NN by_IN group_NN
          interaction_NN term_NN ._. There_EX was_VBD no_DT statistically_RB significant_JJ
          difference_NN in_IN overall_JJ seropositivity_NN between_IN patients_NNS and_CC
          controls_NNS for_IN EBV_NNP VCA_NNP IgG_NNP (_( 68_CD ._. 8_CD %_NN vs_NNS ._. 72_CD ._. 0_CD %_NN ;_: p_NN =_SYM 0_CD ._. 47_CD )_) and_CC
          CMV_NNP IgG_NNP (_( 37_CD ._. 6_CD %_NN vs_NNS ._. 41_CD ._. 7_CD %_NN ;_: p_NN =_SYM 0_CD ._. 36_CD )_) pre-transplant_JJ
          samples_NNS ._. There_EX was_VBD a_DT statistically_RB significant_JJ difference_NN
          in_IN the_DT age_NN measure_NN showing_VBG that_IN the_DT number_NN of_IN EBV_NNP and_CC CMV_NNP
          IgG_NNP seropositive_JJ cases_NNS in_IN pre-treatment_JJ samples_NNS increases_NNS
          with_IN age_NN (_( p_NN <_NN 0_CD ._. 0001_CD ;_: resp_NN ._. p_NN =_SYM 0_CD ._. 0131_CD )_) ._. The_DT
          interaction_NN of_IN age_NN and_CC group_NN measure_NN was_VBD not_RB significant_JJ
          (_( p_NN =_SYM 0_CD ._. 23_CD for_IN EBV_NNP and_CC p_NN =_SYM 0_CD ._. 60_CD for_IN CMV_NNP )_) ._. Overall_RB
          pre-treatment_JJ IgG_NNP seropositivity_NN for_IN HHV-_NNP 6_CD was_VBD
          significantly_RB lower_JJR in_IN patients_NNS than_IN in_IN controls_NNS (_( 80_CD ._. 6_CD %_NN
          vs_NNS ._. 91_CD ._. 3_LS %_NN ;_: p_NN =_SYM 0_CD ._. 0231_CD )_) ._. The_DT age_NN measure_NN was_VBD also_RB
          significantly_RB different_JJ (_( p_NN <_NN 0_CD ._. 0001_CD )_) demonstrating_VBG
          increasing_VBG HHV-_NNP 6_CD IgG_NNP positivity_NN with_IN age_NN ._. The_DT interaction_NN
          of_IN age_NN and_CC group_NN measure_NN for_IN HHV-_NNP 6_CD was_VBD not_RB significant_JJ (_( p_NN
          =_SYM 0_CD ._. 07_CD )_) ._.
          For_IN each_DT age_NN group_NN and_CC each_DT virus_NN ,_, a_DT logistic_JJ
          regression_NN analysis_NN was_VBD performed_VBN with_IN pre-treatment_JJ
          sample_NN as_IN the_DT dichotomous_JJ outcome_NN measure_NN and_CC group_NN
          (_( patients_NNS or_CC controls_NNS )_) as_IN the_DT independent_JJ outcome_NN
          measure_NN ._. There_EX were_VBD no_DT statistically_RB significant_JJ
          differences_NNS between_IN pre-treatment_JJ patient_NN samples_NNS and_CC
          controls_NNS in_IN all_DT age_NN groups_NNS for_IN EBV_NNP VCA_NNP IgG_NNP ,_, CMV_NNP IgG_NNP and_CC
          in_IN the_DT 6_CD -_: 11_CD and_CC 12_CD -_: 17_CD age_NN groups_NNS for_IN HHV-_NNP 6_CD IgG_NNP ._. The_DT only_JJ
          differences_NNS were_VBD noticed_VBN for_IN HHV-_NNP 6_CD in_IN the_DT 0_CD -_: 1_CD and_CC 2_CD -_: 5_CD age_NN
          groups_NNS where_WRB patients_NNS had_VBD lower_JJR IgG_NNP seropositivity_NN then_RB
          the_DT controls_NNS ._. Statistical_NNP data_NNS including_VBG p-values_JJ ,_, odds_NNS
          ratios_NNS and_CC odds_NNS confidence_NN intervals_NNS are_VBP summarized_VBD in_IN
          Table_NNP 2_CD ._.
          The_DT same_JJ analyses_NNS were_VBD performed_VBN with_IN post-treatment_JJ
          patient_NN samples_NNS and_CC controls_NNS ._. There_EX was_VBD increased_VBN overall_JJ
          post-treatment_JJ seropositivity_NN that_WDT was_VBD significantly_RB
          different_JJ from_IN controls_NNS for_IN EBV_NNP VCA_NNP IgG_NNP (_( 86_CD ._. 6_CD %_NN vs_NNS ._. 72_CD ._. 0_CD %_NN ;_:
          p_NN =_SYM 0_CD ._. 0004_CD )_) and_CC CMV_NNP IgG_NNP (_( 67_CD ._. 7_CD %_NN vs_NNS ._. 41_CD ._. 7_CD %_NN ;_: p_NN <_NN 0_CD ._. 0001_CD )_) ._.
          No_DT difference_NN in_IN the_DT age_NN measure_NN was_VBD found_VBN demonstrating_VBG
          that_IN the_DT number_NN of_IN EBV_NNP and_CC CMV_NNP seropositive_JJ cases_NNS in_IN
          post-treatment_JJ samples_NNS does_VBZ not_RB increase_VB with_IN age_NN (_( p_NN =_SYM
          0_CD ._. 87_CD ;_: resp_NN ._. p_NN =_SYM 0_CD ._. 62_CD )_) ._. In_IN case_NN of_IN HHV-_NNP 6_CD IgG_NNP ,_, no_DT
          difference_NN was_VBD found_VBN between_IN post-treatment_JJ samples_NNS and_CC
          controls_NNS (_( 94_CD ._. 3_LS %_NN vs_NNS ._. 91_CD ._. 3_LS %_NN ;_: p_NN =_SYM 0_CD ._. 58_CD )_) ._. The_DT age_NN measure_NN was_VBD
          significantly_RB different_JJ (_( p_NN =_SYM 0_CD ._. 0355_CD )_) demostrating_VBG
          increasing_VBG HHV-_NNP 6_CD IgG_NNP seropositivity_NN with_IN age_NN ._. There_EX was_VBD
          no_DT significant_JJ difference_NN in_IN the_DT interaction_NN of_IN age_NN and_CC
          group_NN measure_NN for_IN EBV_NNP ,_, CMV_NNP and_CC HHV-_NNP 6_CD ,_, respectively_RB (_( p_NN =_SYM
          0_CD ._. 73_CD ;_: p_NN =_SYM 0_CD ._. 57_CD ;_: resp_NN ._. p_NN =_SYM 0_CD ._. 07_CD )_) ._.
          For_IN each_DT age_NN group_NN and_CC each_DT virus_NN ,_, a_DT logistic_JJ
          regression_NN analysis_NN was_VBD performed_VBN with_IN post-treatment_JJ
          sample_NN as_IN the_DT dichotomous_JJ variable_NN and_CC group_NN (_( patients_NNS or_CC
          controls_NNS )_) as_IN the_DT independent_JJ variable_NN ._. There_EX were_VBD
          statistically_RB significant_JJ differences_NNS between_IN
          post-treatment_JJ patient_NN samples_NNS and_CC controls_NNS in_IN the_DT 0_CD -_: 1_CD
          and_CC 2_CD -_: 5_CD age_NN groups_NNS for_IN EBV_NNP VCA_NNP IgG_NNP and_CC in_IN all_DT age_NN groups_NNS
          for_IN CMV_NNP IgG_NNP demonstrating_VBG higher_JJR seropositivity_NN in_IN
          patients_NNS than_IN in_IN controls_NNS ._. No_DT differences_NNS were_VBD noticed_VBN in_IN
          the_DT 6_CD -_: 11_CD and_CC 12_CD -_: 17_CD age_NN groups_NNS for_IN EBV_NNP VCA_NNP IgG_NNP and_CC in_IN all_DT
          age_NN groups_NNS for_IN HHV-_NNP 6_CD IgG_NNP ._. Statistical_NNP data_NNS including_VBG
          p-values_JJ ,_, odds_NNS ratios_NNS and_CC odds_NNS confidence_NN intervals_NNS are_VBP
          summarized_VBD in_IN Table_NNP 2_CD ._. Figure_NN 1_CD demonstrates_VBZ LH_NNP IgG_NNP
          seropositivity_NN in_IN patient_NN pre-_NN and_CC post-treatment_JJ samples_NNS
          and_CC in_IN controls_NNS ._.
          To_TO compare_VB pre-treatment_JJ and_CC post-treatment_JJ samples_NNS ,_, a_DT
          McNemar_NNP test_NN was_VBD performed_VBN for_IN each_DT viral_JJ serology_NN ._. This_DT
          test_NN was_VBD performed_VBN both_DT overall_NN ,_, ignoring_VBG age_NN ,_, and_CC then_RB
          repeated_VBN within_IN each_DT age_NN group_NN ._. Overall_RB McNemar_NNP test_NN
          demonstrated_VBN statistically_RB significant_JJ difference_NN between_IN
          pre-_NN and_CC post-treatment_JJ patient_NN samples_NNS for_IN all_DT three_CD LH_NNP
          (_( p_NN <_NN 0_CD ._. 0001_CD )_) ._. There_EX were_VBD also_RB statistically_RB
          significant_JJ differences_NNS in_IN all_DT age_NN groups_NNS for_IN EBV_NNP (_( age_NN
          group_NN 0_CD -_: 1_CD :_: p_NN =_SYM 0_CD ._. 0016_CD ;_: age_NN group_NN 2_CD -_: 5_CD :_: p_NN =_SYM 0_CD ._. 0003_CD ;_: age_NN
          group_NN 6_CD -_: 11_CD :_: p_NN =_SYM 0_CD ._. 0143_CD ;_: and_CC age_NN group_NN 12_CD -_: 17_CD :_: p_NN =_SYM 0_CD ._. 0455_CD )_) ,_,
          in_IN all_DT age_NN groups_NNS for_IN CMV_NNP (_( age_NN group_NN 0_CD -_: 1_CD :_: 0_CD ._. 0082_CD ;_: age_NN
          group_NN 2_CD -_: 5_CD :_: p_NN <_NN 0_CD ._. 0001_CD ;_: age_NN group_NN 6_CD -_: 11_CD :_: p_NN <_NN 0_CD ._. 0001_CD ;_:
          and_CC age_NN group_NN 12_CD -_: 17_CD :_: p_NN =_SYM 0_CD ._. 0003_CD )_) and_CC in_IN two_CD age_NN groups_NNS
          for_IN HHV-_NNP 6_CD (_( age_NN group_NN 0_CD -_: 1_CD :_: p_NN =_SYM 0_CD ._. 0082_CD ;_: age_NN group_NN 2_CD -_: 5_CD :_:
          0_CD ._. 0016_CD )_) ._. No_DT significant_JJ difference_NN was_VBD found_VBN in_IN the_DT age_NN
          group_NN 6_CD -_: 11_CD (_( p_NN =_SYM 0_CD ._. 08_CD )_) and_CC 12_CD -_: 17_CD (_( p_NN =_SYM 0_CD ._. 15_CD )_) for_IN HHV-_NNP 6_CD ._. The_DT
          data_NNS are_VBP summarized_VBD in_IN Figure_NN 1_CD ._.
          Using_VBG the_DT McNemar_NNP test_NN ,_, we_PRP compared_VBD IgG_NNP seropositivity_NN
          between_IN pre-treatment_JJ and_CC post-treatment_JJ samples_NNS
          according_VBG to_TO cancer_NN diagnosis_NN described_VBD in_IN Table_NNP 1_CD ,_, i_NNP ._. e_SYM ._.
          leukemias_NNS ,_, lymphomas_NNS and_CC solid_JJ tumors_NNS (_( the_DT group_NN of_IN
          histiocytosis_NNS was_VBD not_RB analyzed_VBN this_DT way_NN since_IN the_DT number_NN
          of_IN subjects_NNS was_VBD too_RB small_JJ for_IN statistical_JJ analysis_NN )_) ._. EBV_NNP
          VCA_NNP IgG_NNP ,_, CMV_NNP IgG_NNP and_CC HHV-_NNP 6_CD IgG_NNP seropositivity_NN ,_,
          respectively_RB ,_, was_VBD significantly_RB different_JJ in_IN the_DT leukemia_NN
          group_NN (_( p_NN =_SYM 0_CD ._. 0004_CD ;_: p_NN <_NN 0_CD ._. 0001_CD ;_: resp_NN ._. p_NN =_SYM 0_CD ._. 0245_CD )_) ._.
          There_EX was_VBD also_RB a_DT statistically_RB significant_JJ difference_NN for_IN
          CMV_NNP IgG_NNP in_IN the_DT lymphoma_NN and_CC solid_JJ tumor_NN groups_NNS (_( p_NN =_SYM
          0_CD ._. 0058_CD ;_: resp_NN ._. p_NN =_SYM 0_CD ._. 0008_CD )_) ._. No_DT statistically_RB significant_JJ
          difference_NN was_VBD noticed_VBN for_IN EBV_NNP VCA_NNP IgG_NNP and_CC HHV-_NNP 6_CD IgG_NNP in_IN
          the_DT lymphoma_NN (_( p_NN =_SYM 0_CD ._. 36_CD ;_: resp_NN ._. p_NN =_SYM 0_CD ._. 75_CD )_) and_CC solid_JJ tumor_NN
          (_( p_NN =_SYM 0_CD ._. 25_CD ;_: resp_NN ._. p_NN =_SYM 0_CD ._. 12_CD )_) groups_NNS ._. The_DT data_NNS are_VBP
          summarized_VBD in_IN Figure_NN 2_CD ._.
          Based_VBN on_IN serology_NN ,_, we_PRP were_VBD able_JJ to_TO demonstrate_VB the_DT
          rate_NN of_IN primary_JJ infection_NN and_CC reactivation_NN of_IN LH_NNP in_IN most_JJS
          of_IN the_DT patients_NNS during_IN anticancer_NN treatment_NN ._. The_DT results_NNS
          are_VBP shown_VBN in_IN Figure_NN 3_CD ._. Primary_JJ infection_NN with_IN EBV_NNP and_CC CMV_NNP
          occurs_VBZ in_IN almost_RB 50_CD %_NN of_IN children_NNS less_JJR than_IN 6_CD years_NNS of_IN
          age_NN ._. Primary_JJ HHV-_NNP 6_CD infection_NN is_VBZ less_RBR frequent_JJ ._. In_IN older_JJR
          children_NNS ,_, EBV_NNP and_CC HHV-_NNP 6_CD reactivation_NN also_RB occurs_VBZ ._. We_PRP were_VBD
          able_JJ to_TO distinguish_VB primary_JJ infection_NN from_IN reactivation_NN
          in_IN all_DT cases_NNS of_IN symptomatic_JJ EBV_NNP infection_NN based_VBN on_IN EBNA_NNP
          IgG_NNP status_NN ._. In_IN case_NN of_IN CMV_NNP and_CC HHV-_NNP 6_CD there_EX were_VBD 4_CD and_CC 2_CD
          cases_NNS ,_, respectively_RB ,_, where_WRB it_PRP was_VBD impossible_JJ to_TO
          distinguish_VB that_DT ._. In_IN addition_NN ,_, two_CD of_IN that_DT cases_NNS showed_VBD
          CMV_NNP and_CC HHV-_NNP 6_CD crossreactivity_NN ._.
        
        
          Analysis_NNP of_IN LH_NNP DNA_NNP and_CC comparison_NN with_IN LH_NNP
          serology_NN
          We_PRP examined_VBD 215_CD blood_NN samples_NNS from_IN 70_CD patients_NNS ._. Sixty_CD
          four_CD healthy_JJ individuals_NNS served_VBD as_IN controls_NNS ._. Seventeen_CD
          (_( 24_CD %_NN )_) ,_, 18_CD (_( 26_CD %_NN )_) ,_, and_CC 21_CD (_( 30_CD %_NN )_) patients_NNS were_VBD PCR_NNP EBV_NNP ,_, CMV_NNP
          and_CC HHV-_NNP 6_CD ,_, respectively_RB ,_, (_( +_NN )_) to_TO (_( +_NN +_NN +_NN )_) positive_JJ ._. In_IN
          comparison_NN ,_, 2_CD (_( 3_CD %_NN )_) ,_, 1_CD (_( 2_CD %_NN )_) ,_, and_CC 5_CD (_( 8_CD %_NN )_) healthy_JJ controls_NNS
          were_VBD PCR_NNP EBV_NNP ,_, CMV_NNP and_CC HHV-_NNP 6_CD ,_, respectively_RB ,_, (_( +_NN )_) positive_JJ ;_:
          none_NN was_VBD (_( +_NN +_NN )_) or_CC (_( +_NN +_NN +_NN )_) positive_JJ ._. All_DT cases_NNS of_IN PCR_NNP (_( +_NN +_NN )_) or_CC
          (_( +_NN +_NN +_NN )_) positive_JJ results_NNS obtained_VBN from_IN 10_CD ,_, 8_CD ,_, and_CC 13_CD
          patients_NNS with_IN EBV_NNP ,_, CMV_NNP and_CC HHV-_NNP 6_CD active_JJ symptomatic_JJ
          infection_NN ,_, respectively_RB ,_, corresponded_VBD with_IN serological_JJ
          findings_NNS of_IN recent_JJ infection_NN occurring_VBG 1_CD -_: 5_CD weeks_NNS
          following_VBG the_DT first_JJ PCR_NNP positive_JJ result_NN ._. In_IN case_NN of_IN PCR_NNP
          EBV_NNP ,_, CMV_NNP and_CC HHV-_NNP 6_CD (_( +_NN )_) positive_JJ result_NN ,_, the_DT serology_NN
          finding_VBG of_IN recent_JJ infection_NN corresponded_VBD in_IN 7_CD /_NN 7_CD ,_, 6_CD /_NN 10_CD and_CC
          3_CD /_NN 8_CD patients_NNS ,_, respectively_RB ._. Four_CD and_CC 5_CD patients_NNS were_VBD PCR_NNP
          CMV_NNP and_CC HHV-_NNP 6_CD (_( +_NN )_) positive_JJ ,_, respectively_RB ,_, but_CC lacking_VBG
          serological_JJ evidence_NN of_IN recent_JJ infection_NN ._. Since_IN they_PRP had_VBD
          symptomatic_JJ infection_NN ,_, we_PRP considered_VBD them_PRP being_VBG infected_VBN
          with_IN a_DT particular_JJ virus_NN and_CC all_DT of_IN them_PRP showed_VBD
          serological_JJ evidence_NN of_IN previous_JJ infection_NN in_IN
          post-treatment_JJ samples_NNS ._. Besides_IN that_DT ,_, there_EX were_VBD 4_CD
          patients_NNS PCR_NNP EBV_NNP negative_JJ who_WP demonstrated_VBD recent_JJ
          infection_NN by_IN serology_NN ._. One_CD patient_NN had_VBD coinfection_NN of_IN EBV_NNP
          and_CC HHV-_NNP 6_CD during_IN anticancer_NN treatment_NN detected_VBN by_IN PCR_NNP
          [_NN EBV_NNP (_( +_NN +_NN +_NN )_) positive_JJ ,_, HHV-_NNP 6_CD (_( +_NN )_) ]_NN with_IN serological_JJ evidence_NN
          of_IN primary_JJ EBV_NNP infection_NN and_CC reactivation_NN of_IN HHV-_NNP 6_CD ._.
          Data_NNP summarized_VBD in_IN Table_NNP 3_CD provide_VB the_DT information_NN
          about_IN the_DT differences_NNS in_IN diagnosis_NN of_IN EBV_NNP and_CC CMV_NNP
          infection_NN ._. By_IN combination_NN of_IN serology_NN and_CC DNA_NNP analysis_NN ,_,
          we_PRP were_VBD able_JJ to_TO detect_VB symptomatic_JJ infection_NN more_RBR
          frequently_RB in_IN comparison_NN to_TO serology_NN only_RB (_( p_NN =_SYM 0_CD ._. 013_CD for_IN
          EBV_NNP ;_: p_NN =_SYM 0_CD ._. 007_CD for_IN CMV_NNP )_) ._. As_IN expected_VBN ,_, the_DT rates_NNS of_IN
          "_'' laboratory_NN infection_NN "_'' ,_, defined_VBN as_IN the_DT sum_NN of_IN the_DT cases_NNS
          with_IN symptomatic_JJ infection_NN and_CC positive_JJ seroconversion_NN
          for_IN each_DT virus_NN ,_, were_VBD not_RB significantly_RB different_JJ in_IN these_DT
          two_CD groups_NNS ._. Laboratory_NNP EBV_NNP and_CC CMV_NNP infection_NN was_VBD present_JJ
          in_IN 65_CD (_( 34_CD ._. 9_CD %_NN )_) and_CC 66_CD (_( 35_CD ._. 4_LS %_NN )_) of_IN 186_CD patients_NNS ,_,
          respectively_RB ._. Laboratory_NNP HHV-_NNP 6_CD infection_NN was_VBD present_JJ in_IN
          23_CD (_( 32_CD ._. 9_CD %_NN )_) of_IN 70_CD patients_NNS ._.
        
        
          The_DT influence_NN of_IN blood_NN products_NNS on_IN LH_NNP
          infection_NN
          One_CD hundred_CD fifty_NN six_CD children_NNS (_( 83_CD ._. 9_CD %_NN )_) were_VBD given_VBN at_IN
          least_JJS one_CD blood_NN product_NN transfusion_NN during_IN treatment_NN ._.
          Fifty_NNP four_CD (_( 34_CD ._. 6_CD %_NN )_) and_CC 57_CD (_( 36_CD ._. 5_LS %_NN )_) children_NNS out_IN of_IN 156_CD
          transfused_JJ children_NNS were_VBD infected_VBN with_IN EBV_NNP and_CC CMV_NNP ,_,
          respectively_RB ._. Eleven_CD (_( 36_CD ._. 7_CD %_NN )_) and_CC 9_CD (_( 30_CD ._. 0_CD %_NN )_) children_NNS out_IN
          of_IN 30_CD non-transfused_JJ children_NNS were_VBD infected_VBN with_IN EBV_NNP and_CC
          CMV_NNP ,_, respectively_RB ._. In_IN addition_NN ,_, eighteen_NN (_( 29_CD ._. 5_LS %_NN )_) out_IN of_IN
          61_CD children_NNS transfused_JJ in_IN the_DT period_NN from_IN 1997_CD through_IN
          1999_CD were_VBD infected_VBN with_IN HHV-_NNP 6_CD while_IN 5_CD (_( 55_CD ._. 6_CD %_NN )_) children_NNS
          out_IN of_IN 9_CD non-transfused_JJ children_NNS were_VBD infected_VBN with_IN
          HHV-_NNP 6_CD ._. There_EX was_VBD no_DT statistically_RB significant_JJ difference_NN
          in_IN the_DT incidence_NN of_IN EBV_NNP (_( p_NN =_SYM 0_CD ._. 64_CD )_) ,_, CMV_NNP (_( p_NN =_SYM 0_CD ._. 16_CD )_) or_CC
          HHV-_NNP 6_CD (_( p_NN =_SYM 0_CD ._. 24_CD )_) infection_NN in_IN between_IN transfused_JJ and_CC
          non-transfused_JJ patients_NNS ._.
        
      
      
        Discussion_NNP
        Frequent_JJ infection_NN with_IN herpesviruses_NNS has_VBZ long_RB been_VBN
        recognized_VBN in_IN patients_NNS undergoing_VBG allogeneic_JJ
        transplantation_NN [_NN 7_CD 8_CD ]_NN and_CC in_IN patients_NNS with_IN acute_JJ leukemia_NN
        [_NN 1_CD 2_CD ]_NN ._. In_IN patients_NNS with_IN acute_JJ leukemia_NN it_PRP has_VBZ been_VBN
        reported_VBN that_IN as_RB many_JJ as_IN two_CD thirds_NNS of_IN seropositive_JJ
        patients_NNS can_MD develop_VB reactivation_NN of_IN herpes_NNS simplex_NN virus_NN
        infection_NN during_IN remission_NN induction_NN therapy_NN [_NN 26_CD ]_NN ._. The_DT
        risk_NN of_IN CMV_NNP infection_NN in_IN acute_JJ leukemia_NN patients_NNS was_VBD
        recognized_VBN almost_RB 30_CD years_NNS ago_RB [_NN 27_CD ]_NN but_CC is_VBZ of_IN particular_JJ
        concern_NN in_IN patients_NNS undergoing_VBG allogeneic_JJ transplantation_NN [_NN
        2_CD 28_CD ]_NN ._. EBV_NNP infection_NN is_VBZ frequently_RB associated_VBN with_IN
        post-transplantation_JJ lymphoproliferative_JJ disorders_NNS in_IN T_NN
        cell-depleted_JJ grafts_NNS [_NN 29_CD ]_NN ._. As_IN recently_RB reported_VBN ,_, HHV-_NNP 6_CD
        can_MD also_RB be_VB associated_VBN with_IN bone_NN marrow_NN supression_NN [_NN 30_CD ]_NN ,_,
        encephalitis_NNS and_CC pneumonitis_NNS [_NN 7_CD 8_CD ]_NN after_IN allogeneic_JJ
        transplantation_NN ._.
        Whether_IN symptomatic_JJ LH_NNP infection_NN occurs_VBZ in_IN chemotherapy-_NN
        and_CC /_NN or_CC radiotherapy-treated_JJ cancer_NN patients_NNS has_VBZ not_RB been_VBN
        reported_VBN ._. This_DT report_NN demonstrates_VBZ for_IN the_DT first_JJ time_NN that_IN
        LH_NNP infection_NN affects_VBZ more_JJR than_IN one_CD third_NN of_IN children_NNS
        treated_VBN for_IN cancer_NN ._. EBV_NNP and_CC CMV_NNP infection_NN occurred_VBD in_IN
        almost_RB 50_CD %_NN of_IN children_NNS younger_JJR then_RB 6_CD years_NNS during_IN
        anticancer_NN treatment_NN ._. At_IN the_DT time_NN of_IN cancer_NN diagnosis_NN the_DT
        rate_NN of_IN EBV_NNP and_CC CMV_NNP seropositivity_NN was_VBD not_RB different_JJ in_IN
        cancer_NN patients_NNS and_CC healthy_JJ controls_NNS ._. On_IN the_DT other_JJ hand_NN ,_,
        children_NNS in_IN all_DT age_NN groups_NNS reached_VBD similar_JJ EBV_NNP and_CC CMV_NNP
        seropositivity_NN levels_NNS after_IN anticancer_NN treatment_NN comparing_VBG
        to_TO healthy_JJ adult_NN controls_NNS ._. It_PRP suggests_VBZ that_WDT children_NNS
        immunosupressed_JJ by_IN chemotherapy_NN and_CC /_NN or_CC radiotherapy_NN have_VBP
        high_JJ incidence_NN of_IN LH_NNP infection_NN ._. As_IN expected_VBN ,_, primary_JJ
        infection_NN was_VBD the_DT most_RBS frequent_JJ in_IN younger_JJR patients_NNS and_CC
        reactivation_NN occurred_VBD in_IN older_JJR patients_NNS ._. In_IN case_NN of_IN HHV-_NNP 6_CD
        infection_NN ,_, which_WDT affects_VBZ most_JJS of_IN humans_NNS by_IN the_DT age_NN of_IN 2_CD
        years_NNS ,_, we_PRP were_VBD surprised_VBN with_IN low_JJ frequency_NN of_IN IgG_NNP
        antibodies_NNS in_IN pre-treatment_JJ samples_NNS as_IN compared_VBN with_IN
        age-matched_JJ healthy_JJ controls_NNS ._. There_EX might_MD be_VB at_IN least_JJS two_CD
        possible_JJ mechanisms_NNS involved_VBN ._. First_LS ,_, due_JJ to_TO either_CC lower_JJR
        sensitivity_NN to_TO detect_VB HHV-_NNP 6_CD IgG_NNP antibodies_NNS by_IN IFA_NNP or_CC due_JJ to_TO
        immune_JJ supression_NN at_IN the_DT time_NN of_IN cancer_NN diagnosis_NN but_CC
        similar_JJ pattern_NN was_VBD not_RB seen_VBN for_IN EBV_NNP or_CC CMV_NNP ._. Second_JJ ,_, due_JJ to_TO
        the_DT possibility_NN that_IN prior_JJ infection_NN with_IN HHV-_NNP 6_CD might_MD be_VB
        directly_RB or_CC indirectly_RB protective_JJ against_IN tumor_NN
        development_NN ._. This_DT finding_VBG would_MD be_VB in_IN agreement_NN with_IN
        Greaves_NNP hypothesis_NNS [_NN 31_CD 32_CD ]_NN which_WDT predicted_VBD an_DT increased_VBN
        risk_NN of_IN B-_NNP cell_NN precursor_NN ALL_NNP for_IN those_DT of_IN higher_JJR
        socioeconomic_JJ level_NN ,_, firstborn_NN children_NNS ,_, and_CC those_DT with_IN
        delayed_VBN or_CC diminished_VBN exposure_NN to_TO common_JJ infections_NNS in_IN
        infancy_NN ._. When_WRB we_PRP studied_VBD our_PRP$ patient_NN population_NN based_VBN on_IN
        cancer_NN diagnosis_NN ,_, the_DT only_RB statistically_RB significant_JJ
        difference_NN between_IN pre-_NN and_CC post-treatment_JJ samples_NNS was_VBD
        noticed_VBN in_IN patients_NNS with_IN leukemia_NN (_( p_NN =_SYM 0_CD ._. 0245_CD )_) but_CC not_RB in_IN
        patients_NNS with_IN lymphoma_NN or_CC solid_JJ cancer_NN (_( Figure_NN 2_LS )_) ._. To_TO our_PRP$
        knowledge_NN ,_, there_EX are_VBP no_DT other_JJ data_NN in_IN the_DT literature_NN
        describing_VBG a_DT protective_JJ effect_NN of_IN HHV-_NNP 6_CD infection_NN in_IN
        infancy_NN against_IN leukemia_NN ._. Further_RB studies_VBZ would_MD be_VB needed_VBN
        to_TO test_VB this_DT association_NN ._.
        As_IN previously_RB demonstrated_VBN ,_, the_DT risk_NN of_IN
        transfusion-acquired_JJ CMV_NNP infection_NN can_MD be_VB significantly_RB
        reduced_VBN by_IN the_DT use_NN of_IN CMV-seronegative_NNP or_CC filtered_VBN (_( white_JJ
        blood_NN cell_NN reduced_VBN )_) blood_NN products_NNS [_NN 33_CD ]_NN ._. In_IN an_DT effort_NN to_TO
        illustrate_VB the_DT role_NN of_IN leukodepleted_JJ blood_NN transfusions_NNS in_IN
        transmission_NN of_IN LH_NNP infection_NN in_IN pediatric_JJ oncology_NN patients_NNS
        we_PRP studied_VBD both_DT populations_NNS :_: a_DT population_NN of_IN patients_NNS
        treated_VBN with_IN leukodepleted_JJ irradiated_JJ blood_NN products_NNS and_CC a_DT
        population_NN of_IN patients_NNS that_WDT did_VBD not_RB required_VBN any_DT blood_NN
        transfusion_NN during_IN anticancer_NN treatment_NN ._. No_DT statistically_RB
        significant_JJ difference_NN for_IN each_DT LH_NNP virus_NN was_VBD found_VBN in_IN these_DT
        two_CD groups_NNS ._. Those_DT data_NNS are_VBP in_IN accordance_NN with_IN recently_RB
        published_VBN prospective_JJ study_NN by_IN Preiksaikis_NNP et_CC al_NN ._. [_NN 34_CD ]_NN
        where_WRB the_DT risk_NN of_IN transfusion-acquired_JJ CMV_NNP infection_NN was_VBD
        estimated_VBN to_TO be_VB less_JJR than_IN 1_CD in_IN 698_CD donor_NN exposures_NNS in_IN
        children_NNS with_IN cancer_NN ._.
        In_IN the_DT literature_NN describing_VBG LH_NNP detection_NN by_IN PCR_NNP ,_, the_DT
        results_NNS vary_VBP widely_RB since_IN different_JJ protocols_NNS have_VBP been_VBN
        used_VBN in_IN different_JJ biological_JJ materials_NNS [_NN 7_CD 8_CD 9_CD 10_CD 14_CD ]_NN ._.
        PCR_NNP method_NN was_VBD used_VBN in_IN patients_NNS undergoing_VBG BMT_NNP or_CC organ_NN
        transplants_NNS but_CC not_RB in_IN chemotherapy-only_JJ and_CC /_NN or_CC
        radiotherapy-only_JJ treated_VBN patients_NNS ._. To_TO our_PRP$ knowledge_NN ,_, this_DT
        report_NN demonstrates_VBZ for_IN the_DT first_JJ time_NN a_DT correlation_NN of_IN
        serological_JJ results_NNS with_IN viral_JJ load_NN detected_VBN by_IN PCR_NNP in_IN
        children_NNS with_IN different_JJ types_NNS of_IN cancer_NN ._. By_IN using_VBG healthy_JJ
        controls_NNS and_CC setting_VBG the_DT threshold_NN of_IN PCR_NNP positive_JJ versus_CC
        negative_JJ based_VBN on_IN correlation_NN with_IN clinical_JJ symptoms_NNS and_CC
        serology_NN ,_, acute_JJ LH_NNP infection_NN could_MD be_VB identified_VBN in_IN most_JJS of_IN
        the_DT cases_NNS ._. The_DT highest_JJS incidence_NN of_IN LH_NNP infection_NN occurred_VBD
        among_IN patients_NNS with_IN leukemia_NN ._. It_PRP probably_RB corresponds_NNS with_IN
        the_DT length_NN of_IN neutropenia_NN and_CC severity_NN of_IN immunosupression_NN
        that_WDT is_VBZ greater_JJR in_IN patients_NNS treated_VBN for_IN leukemia_NN compared_VBN
        to_TO patients_NNS with_IN lymphoma_NN or_CC solid_JJ tumor_NN ._.
      
      
        Conclusion_NNP
        This_DT paper_NN demonstrates_VBZ that_IN EBV_NNP ,_, CMV_NNP and_CC HHV-_NNP 6_CD
        infection_NN is_VBZ frequent_JJ in_IN children_NNS treated_VBN for_IN cancer_NN ,_, is_VBZ
        not_RB transfusion-dependant_JJ ,_, and_CC is_VBZ often_RB associated_VBN with_IN
        clinical_JJ symptoms_NNS ._. Combination_NNP of_IN serology_NN and_CC PCR_NNP method_NN
        in_IN detection_NN of_IN symptomatic_JJ disease_NN is_VBZ superior_JJ to_TO serology_NN
        alone_RB ._. Further_RB studies_VBZ are_VBP needed_VBN to_TO identify_VB patients_NNS at_IN
        higher_JJR risk_NN of_IN severe_JJ LH_NNP infection_NN to_TO prevent_VB
        disease-associated_JJ morbidity_NN and_CC to_TO test_VB the_DT hypothesis_NNS
        that_IN HHV-_NNP 6_CD infection_NN early_RB in_IN the_DT infancy_NN may_MD be_VB protective_JJ
        against_IN leukemia_NN in_IN the_DT frame_NN of_IN Greaves_NNP hypothesis_NNS ._.
      
      
        Abbreviations_NNP
        FN_NNP febrile_NN neutropenia_NN
        LH_NNP lymphotropic_JJ herpesviruses_NNS
        EBV_NNP Epstein-_NNP Barr_NNP virus_NN
        CMV_NNP cytomegalovirus_JJ
        HHV-_NNP 6_CD human_JJ herpesvirus_JJ 6_CD
        BMT_NNP bone_NN marrow_NN transplantation_NN
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD ._.
      
    
  
